


Stabilis



Clindamycin phosphate



Noms commerciaux

Alfaclindamycine	Egypte
Bacoff	Mexique
Biodaclin	Mexique
Camyda	Inde
Cinbiot	Mexique
Clendazaf	Mexique
Cleocin	Autriche, Etats Unis d'Amérique, Turquie
Climicimed	Pérou
Clin	Turquie
Clinamsa	Mexique
Clinbac	Colombie
Clincina	Portugal
Clinda	Allemagne
Clinda Hameln	Allemagne
Clindabiotic	Brésil
Clindacid	Vénézuela
Clindacin	Brésil, Malaisie, Pérou
Clindahexal	Allemagne
Clindalaf	Argentine
Clindamicina	Argentine, Chili, Colombie, Equateur, Espagne, Italie, Mexique, Pérou, Portugal, Vénézuela
Clindamycin	Allemagne, Arabie Saoudite, Autriche, Canada, Etats Unis d'Amérique, Iran, Norvège, Roumanie, Suède
Clindamycine	Belgique, Pays bas
Clindanovag	Argentine
Clindarix	Brésil
Clindasol	Allemagne
Clindaval	Vénézuela
Clindazyn	Mexique
Clindo	Pologne
Clinwas	Chili, Espagne
Clysvic	Mexique
Curamin	Mexique
Daclin	Chili

Dalacin	Arabie Saoudite, Australie, Autriche, Belgique, Canada, Chili, Danemark, Egypte, Emirats Arabes Unis, Equateur, Espagne, Finlande, Grande Bretagne, Grèce, Hongrie, Inde, Iran, Irlande, Islande, Italie, Luxembourg, Malaisie, Mexique, Norvège, Nouvelle Zélande, Pays bas, Pologne, Suède, Suisse, Tunisie, Vénézuéla
Dalacine	France
Daladic	Iran
Dalcinex	Inde
Dalcynvasc	Pérou
Damclid	Inde
Damicin	Mexique
Damicine	Colombie
Dolarclin	Colombie
Euroclin	Colombie, Equateur
Galecin	Mexique
Gynasafe	Inde
Indamid	Mexique
Klimicin	Hongrie, Pologne
Klindan	Turquie
Klindaver	Turquie
Lanacine	Autriche
Lincocin	Malaisie
Lincosa	Malaisie
Meneklin	Turquie
Oklarín	Mexique
Sobelin	Allemagne
Strimia	Mexique
Tidact	Malaisie
Turimycin	Allemagne



Stabilité des solutions

		15 mg/ml	22°C		91			80
		15 mg/ml	4°C		91			80
		6, 9 & 12 mg/ml	-10°C		56			566
		6, 9 & 12 mg/ml	25°C		16			566
		6, 9 & 12 mg/ml	4°C		32			566
		9 mg/ml	24°C		24			421
		9 mg/ml	25°C		48			418
		9 mg/ml	25°C		48			565

		9 & 12 mg/ml	25°C		48				432
		6, 9 & 12 mg/ml	-10°C		56				566
		6, 9 & 12 mg/ml	25°C		16				566
		6, 9 & 12 mg/ml	4°C		32				566
		6 & 12 mg/ml	-10°C		68				567
		6 & 12 mg/ml	25°C		22				567
		6 & 12 mg/ml	5°C		54				567
		9 mg/ml	-20°C		28				565
		9 mg/ml	24°C		24				421
		6 mg/ml	-20°C		30				575
		3 mg/ml	22°C		24				1067
		3 mg/ml	4°C		24				1067
		6 & 12 mg/ml	23°C		7				1815
		6 & 12 mg/ml	4°C		30				1815
		150 mg/ml	22°C-23°C		48				639
		60 mg/ml	25°C		48				644
		2 & 12 mg/ml	25°C		24				604
		2 & 12 mg/ml	4°C		10				604
		9,5 mg/ml	2-8°C		49				4622
		9,5 mg/ml	25°C		24				4622
		9,5 mg/ml	2-8°C		47				4619
		9,5 mg/ml	25°C		24				4619



Stabilité en mélange

		12 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
		9 mg/ml	24°C		Cefotaxime sodium : 20 mg/ml	24		421
		9 mg/ml	24°C		Netilmicin sulfate : 3 mg/ml	24		421
		9 mg/ml	25°C		Cefoxitin sodium : 20 mg/ml	48		418
		9 mg/ml	25°C		Cefamandole nafate : 10 mg/ml	48		418
		9 mg/ml	25°C		Cefazolin sodium : 10 mg/ml	48		418
		9 mg/ml	25°C		Aztreonam : 20 mg/ml	48		432

		9 mg/ml	25°C		Piperacillin sodium : 40 mg/ml	48		432
		12 mg/ml	25°C		Cefoperazone sodium : 20 mg/ml	48		644
		12 mg/ml	25°C		Cefonicid sodium : 10 mg/ml	48		644
		9 mg/ml	25°C		Cefuroxime sodium : 15 mg/ml	48		644
		12 mg/ml	25°C		Ceftriaxone disodium : 20 mg/ml	8		432
		9 mg/ml	25°C		Cefazolin sodium : 10 mg/ml Gentamicin sulfate : 0,8 mg/ml	12		695
		9 mg/ml	25°C		Ceftizoxime sodium : 20 mg/ml	24		418
		9 mg/ml	25°C		Ceftazidime : 20 mg/ml	48		432
		60 mg/ml	25°C		Aztreonam : 200 mg/ml	48		644
		12 mg/ml	25°C		Ceftriaxone disodium : 20 mg/ml	1		432
		9 mg/ml	25°C		Cefazolin sodium : 10 mg/ml Gentamicin sulfate : 0,8 mg/ml	1		695
		9 mg/ml	25°C		Ceftazidime : 20 mg/ml	24		432
		9 mg/ml	25°C		Ceftizoxime sodium : 20 mg/ml	48		418
	RL	12 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
		12 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8		280
		6 mg/ml	25°C		Ofloxacin : 2 mg/ml	48		889
PVC		9 mg/ml	-20°C		Gentamicin sulfate : 1,2 mg/ml	28		565
PVC		3 & 6 mg/ml	22°C-23°C		Aztreonam : 10 & 20 mg/ml	48		419
PVC		9 mg/ml	24°C		Cefotaxime sodium : 20 mg/ml	24		421
PVC		9 mg/ml	24°C		Netilmicin sulfate : 3 mg/ml	24		421
PVC		9 mg/ml	25°C		Amikacin sulfate : 4 mg/ml	48		565
PVC		3 & 6 mg/ml	4°C		Aztreonam : 10 & 20 mg/ml	7		419
PVC		9 mg/ml	-20°C		Tobramycin sulfate : 1,2 mg/ml	28		565
PVC		9 mg/ml	-20°C		Tobramycin sulfate : 1,2 mg/ml	14		565
PVC		6 mg/ml	25°C		Gentamicin sulfate : 5 mg/ml	24		423
		90 mg/ml	22°C-23°C		Gentamicin sulfate : 30 mg/ml	48		639
		90 mg/ml	22°C-23°C		Amikacin sulfate : 190 mg/ml	48		639



Facteur influençant la stabilité

	PH >7			3526
--	-------	--	--	------



Compatibilités

	Clindamycin phosphate : 6 mg/ml Amiodarone hydrochloride : 4 mg/ml		385	
	Clindamycin phosphate : 10 mg/ml		1415	
	Clindamycin phosphate : 12 mg/ml Aciclovir sodium : 5 mg/ml		336	
		Clindamycin phosphate : 10 mg/ml Allopurinol sodium : 3 mg/ml		307
	Clindamycin phosphate : 10 mg/ml Amifostine : 10 mg/ml		3	
	Clindamycin phosphate : 90 mg/ml Amikacin sulfate : 75 mg/ml		639	
	Clindamycin phosphate Amikacin sulfate		3526	
	Clindamycin phosphate : 9 mg/ml Amikacin sulfate : 4 mg/ml		565	
		Clindamycin phosphate Aminophylline	3526	
		Clindamycin phosphate Amobarbital sodium	3526	
		Clindamycin phosphate : 150 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml	3824	
	Clindamycin phosphate : 10 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921	
	Clindamycin phosphate : 5,77 mg/ml		4440	
	Clindamycin phosphate : 10 mg/ml		3967	
		Clindamycin phosphate Ampicillin sodium	3526	
	Clindamycin phosphate Aztreonam		3526	
	Clindamycin phosphate : 6 mg/ml Aztreonam : 10 mg/ml		419	
	Clindamycin phosphate : 3 mg/ml Aztreonam : 10 mg/ml		419	
	Clindamycin phosphate : 3 mg/ml Aztreonam : 20 mg/ml		419	
	Clindamycin phosphate : 6 mg/ml Aztreonam : 20 mg/ml		419	
	Clindamycin phosphate : 150 mg/ml Caffeine : 10 mg/ml		3964	

		Clindamycin phosphate Calcium gluconate		3526
		Clindamycin phosphate : 3 mg/ml		1055
		Clindamycin phosphate : 24 mg/ml		3379
		Clindamycin phosphate : 150 mg/ml		999
		Clindamycin phosphate : 10 mg/ml Amsacrine : 1 mg/ml		253
		Clindamycin phosphate : 9 mg/ml Aztreonam : 20 mg/ml		432
		Clindamycin phosphate : 10 mg/ml		301
		Clindamycin phosphate : 9 mg/ml Atosiban : 0,75 mg/ml		4642
		Clindamycin phosphate : 30 mg/ml Azithromycine : 2 mg/ml		1800
		Clindamycin phosphate : 10 mg/ml Bivalirudin : 5 mg/ml		1713
		Clindamycin phosphate		3526
		Clindamycin phosphate : 10 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Clindamycin phosphate : 10 mg/ml Aztreonam : 40 mg/ml		99
		Clindamycin phosphate : 60 mg/ml Aztreonam : 200 mg/ml		644
		Clindamycin phosphate Calcium gluconate		3644
		Clindamycin phosphate : 60 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Clindamycin phosphate : 10 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Clindamycin phosphate Cefamandole nafate		3526
		Clindamycin phosphate : 9 mg/ml Cefamandole nafate : 10 mg/ml		418
		Clindamycin phosphate Cefazolin sodium		3526
		Clindamycin phosphate : 9 mg/ml Cefazolin sodium : 10 mg/ml		418
		Clindamycin phosphate : 0,25 & 6 mg/ml Cefepime dihydrochloride : 4 & 40 mg/ml		3548
		Clindamycin phosphate : 10 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Clindamycin phosphate : 12 mg/ml Cefonicid sodium : 10 mg/ml		644
		Clindamycin phosphate : 12 mg/ml Cefoperazone sodium : 20 mg/ml		644
		Clindamycin phosphate : 9 mg/ml Cefotaxime sodium : 20 mg/ml		421
		Clindamycin phosphate Cefotaxime sodium		3526

	Clindamycin phosphate : 9 mg/ml Cefoxitin sodium : 20 mg/ml		418
	Clindamycin phosphate Cefoxitin sodium		3526
	Clindamycin phosphate : 12 mg/ml Cefpirome sulfate : 50 mg/ml		280
	Clindamycin phosphate : 12 mg/ml Cefpirome sulfate : 50 mg/ml	RL	280
	Clindamycin phosphate : 12 mg/ml Cefpirome sulfate : 50 mg/ml		280
	Clindamycin phosphate : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
	Clindamycin phosphate : 10 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
	Clindamycin phosphate Ceftazidime		3526
	Clindamycin phosphate : 9 mg/ml Ceftazidime : 20 mg/ml		432
	Clindamycin phosphate Ceftizoxime sodium		3526
	Clindamycin phosphate : 9 mg/ml Ceftizoxime sodium : 20 mg/ml		418
	Clindamycin phosphate : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
	Clindamycin phosphate : 10 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
	Clindamycin phosphate Ceftriaxone disodium		3526
	Clindamycin phosphate : 12 mg/ml Ceftriaxone disodium : 20 mg/ml		432
	Clindamycin phosphate : 9 mg/ml Cefuroxime sodium : 15 mg/ml		644
	Clindamycin phosphate : 1.2 mg/ml Cimetidine hydrochloride : 1.2 & 5 mg/ml		1201
	Clindamycin phosphate Ciprofloxacin lactate		3526
	Clindamycin phosphate : 7 mg/ml Ciprofloxacin lactate : 1.5 mg/ml		434
	Clindamycin phosphate : 10 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Clindamycin phosphate : 150 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Clindamycin phosphate : 10 mg/ml Dexmedetomidine : 4 µg/ml		1712
	Clindamycin phosphate : 12 & 150 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
	Clindamycin phosphate Dimenhydrinate		2087
	Clindamycin phosphate : 10 mg/ml Docetaxel : 0.9 mg/ml		1754
	Clindamycin phosphate : 10 mg/ml Doxapram hydrochloride : 2 mg/ml		1802

		Clindamycin phosphate : 10 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Clindamycin phosphate : 9 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Clindamycin phosphate : 9 mg/ml Esmolol hydrochloride : 10 mg/ml		384
		Clindamycin phosphate : 10 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Clindamycin phosphate : 10 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Clindamycin phosphate : 9 mg/ml Fentanyl citrate : 50 µg/ml		63
		Clindamycin phosphate : 10 mg/ml Filgrastim : 30 µg/ml		244
		Clindamycin phosphate : 12 mg/ml Fluconazole : 2 mg/ml		256
		Clindamycin phosphate : 24 mg/ml Fluconazole : 2 mg/ml		496
		Clindamycin phosphate : 10 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Clindamycin phosphate : 24 mg/ml Foscarnet sodium : 24 mg/ml		73
		Clindamycin phosphate : 12 mg/ml Foscarnet sodium : 24 mg/ml		1135
		Clindamycin phosphate : 10 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Clindamycin phosphate : 90 mg/ml Gentamicin sulfate : 12 mg/ml		639
		Clindamycin phosphate : 6 mg/ml Gentamicin sulfate : 0.67 mg/ml		423
		Clindamycin phosphate Gentamicin sulfate		3526
		Clindamycin phosphate : 10 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Clindamycin phosphate : 12 mg/ml Heparin sodium : 50 UI/ml		317
		Clindamycin phosphate : 10 mg/ml Hetastarch : 60 mg/ml		1721
		Clindamycin phosphate : 12 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Clindamycin phosphate Idarubicin hydrochloride		3526
		Clindamycin phosphate : 12 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Clindamycin phosphate : 150 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Clindamycin phosphate : 9 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Clindamycin phosphate : 10 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Clindamycin phosphate : 150 mg/ml Levofloxacin : 5 mg/ml		1072

		Clindamycin phosphate : 10 mg/ml Linezolid : 2 mg/ml	∅	1925
		Clindamycin phosphate Magnesium sulfate		3526
		Clindamycin phosphate : 12 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml	♦	1047
		Clindamycin phosphate Magnesium sulfate		3838
		Clindamycin phosphate : 10 mg/ml Melphalan : 0.1 mg/ml	▲	169
		Clindamycin phosphate : 150 mg/ml Meropenem : 50 mg/ml	💧	4319
		Clindamycin phosphate Methohexital sodium		3526
		Clindamycin phosphate Metronidazole		3594
		Clindamycin phosphate : 10 mg/ml Metronidazole : 5 mg/ml	∅	1035
		Clindamycin phosphate : 9 mg/ml Midazolam hydrochloride : 1 mg/ml	♦	176
		Clindamycin phosphate : 12 mg/ml Morphine sulfate : 1 mg/ml	♦	405
		Clindamycin phosphate : 150 mg/ml N-acetylcysteine : 200 mg/ml	∅	3766
		Clindamycin phosphate : 150 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Clindamycin phosphate : 9 mg/ml Netilmicin sulfate : 3 mg/ml	▲♦	421
		Clindamycin phosphate Netilmicin sulfate	▲♦	3526
		Clindamycin phosphate : 9 mg/ml Nicardipine hydrochloride : 0.1 mg/ml	▲♦	1490
		Clindamycin phosphate : 6 mg/ml Ofloxacin : 2 mg/ml	∅	889
		Clindamycin phosphate : 10 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	334
		Clindamycin phosphate : 12 mg/ml Oritavancin : 0.8 >>2 mg/ml	♦	3152
		Clindamycin phosphate Pantoprazole sodium		2090
		Clindamycin phosphate : 150 mg/ml Paracetamol : 10 mg/ml		4742
		Clindamycin phosphate : 10 mg/ml Paracetamol : 10 mg/ml	∅	3571
		Clindamycin phosphate : 10 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
		Clindamycin phosphate Pentobarbital sodium		3526
		Clindamycin phosphate : 12 mg/ml Pethidine hydrochloride : 10 mg/ml	♦	405
		Clindamycin phosphate Phenobarbital sodium		3526

		Clindamycin phosphate Phenytoin sodium		3526
		Clindamycin phosphate : 18 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Clindamycin phosphate : 9 mg/ml Piperacillin sodium : 40 mg/ml		432
		Clindamycin phosphate Piperacillin sodium		3526
		Clindamycin phosphate : 10 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Clindamycin phosphate : 10 mg/ml Propofol : 10 mg/ml		300
		Clindamycin phosphate Ranitidine hydrochloride		3526
		Clindamycin phosphate : 10 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Clindamycin phosphate : 150 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Clindamycin phosphate : 10 mg/ml Sargramostim : 10 µg/ml		335
		Clindamycin phosphate Sodium bicarbonate		3526
		Clindamycin phosphate : 12 mg/ml Tacrolimus : 1000 µg/ml		479
		Clindamycin phosphate : 12 mg/ml Temocilline : 83.33 mg/ml		2231
		Clindamycin phosphate : 10 mg/ml Teniposide : 0.1 mg/ml		905
		Clindamycin phosphate : 12 mg/ml Theophylline : 4 mg/ml		317
		Clindamycin phosphate : 150 mg/ml Thiopental sodium : 25 mg/ml		3767
		Clindamycin phosphate Thiopental sodium		3526
		Clindamycin phosphate : 10 mg/ml Thiotepa : 1 mg/ml		249
		Clindamycin phosphate Tobramycin sulfate		3526
		Clindamycin phosphate : 90 mg/ml Tobramycin sulfate : 12 mg/ml		639
		Clindamycin phosphate : 6 mg/ml Tramadol hydrochloride : 0,4 mg/ml		2002
		Clindamycin phosphate : 1.2 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Clindamycin phosphate : 10 mg/ml Vinorelbine tartrate : 1 mg/ml		84
		Clindamycin phosphate : 12 mg/ml Zidovudine : 4 mg/ml		337



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
80	Revue	Nahata MC, Morosco RS, Hipple TF. Stability of cimetidine hydrochloride and of clindamycin phosphate in water for injection stored in glass vials at two temperatures. Am J Hosp Pharm 1993 ; 50: 2559-2561.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.

249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
256	Revue	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
280	Revue	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of ceftiofime sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
385	Revue	Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118.

386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
418	Revue	Bosso JA, Townsend RJ. Stability of clindamycin phosphate and ceftizoxime sodium, cefoxitine sodium, cefamandole nafate, or cefazolin sodium in two intravenous solutions. Am J Hosp Pharm 1985 ; 42: 2211-2214.
419	Revue	James MJ, Riley CM. Stability of intravenous admixtures of aztreonam and clindamycin phosphate. Am J Hosp Pharm 1985 ; 42: 1984-1986.
421	Revue	Foley PT, Bosso JA, Bair JN, Townsend RJ. Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures. Am J Hosp Pharm 1985 ; 42: 839-843.
423	Revue	Mansur JM, Abramowitz PW, Lerner SA, Smith RB, Townsend RJ. Stability and cost analysis of clindamycin-gentamicin admixtures given every eight hours. Am J Hosp Pharm 1985 ; 42: 332-335.
432	Revue	Marble DA, Bosso JA, Townsend RJ. Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions. Am J Hosp Pharm 1986 ; 43: 1732-1736.
434	Revue	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
565	Revue	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. Drug Intell Clin Pharm 1986 ; 20: 960-963.
566	Revue	Porter WR, Johnson CA, Cohon MS, Gillespie W. Compatibility and stability of clindamycin phosphate with intravenous fluids. Am J Hosp Pharm 1983 ; 40: 91-94.
567	Revue	Das Gupta V, Parasrampur J, Bethea C, Wright W. Stability of clindamycin phosphate in dextrose and saline solutions. Can J Hosp Pharm 1989 ; 42: 109-112.
575	Revue	Holmes CJ, Ausman RK, Kundsinn RB, Walter CW. Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags. Am J Hosp Pharm 1982 ; 39: 104-108.

604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
639	Revue	Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ. Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes. Drug Intell Clin Pharm 1987 ; 21: 806-810.
644	Revue	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles. Drug Intell Clin Pharm 1988 ; 22: 54-57.
695	Revue	Zbrozek AS, Marble DA, Bosso JA. Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions. Drug Intell Clin Pharm 1988 ; 22: 873-875.
889	Revue	Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
999	Revue	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1035	Revue	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1047	Revue	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1055	Revue	Faragos S. Compatibility of antibiotics and other drugs in total parenteral nutrition solutions. Can J Hosp Pharm 1983 ; 36: 43-52.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1067	Revue	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1072	Revue	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1201	Revue	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.

1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1802	Revue	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1815	Revue	Xu QA, Trissel LA. Stability of clindamycin phosphate in autodose infusion system bags. Int J Pharm Compound 2003 ; 7, 2: 149-151.
1925	Revue	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.





















































1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2002	Revue	Abanmy NO, Zaghoul IY, Radwan MA. Compatibility of tramadol hydrochloride injection with selected drugs and solutions. Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3379	Revue	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3548	Laboratoire	Cefepime (Maxipime®) - Summary of Product characteristics. Bristol Myers Squibb 2007

3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3594	Laboratoire	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3644	Laboratoire	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhi R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	Revue	Staven V, Herra I, Wang S, Grönlie I, Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4440	Revue	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4619	Laboratoire de contrôle qualité	Simms D, Roberts J, Rigge D. Stability Study for Clindamycin 9.52mg/mL in 5.0% w/v Glucose 50mL Infusion Bags. Quality Control North West, Stockport NHS Foundati 2021
4622	Laboratoire de contrôle qualité	Simms D, Roberts J, Rigge D. Stability Study for Clindamycin 9.52mg/mL in 0.9% w/v Sodium Chloride 50mL Infusion Bags. Quality Control North West, Stockport NHS Foundati 2021
4642	Poster	Larossa garcia M, Jimenez-Lozano I, Boix-Montanés A, Mallandrich Miret M, Clemente Bautista M, cabanas Poy M.J., Gorgas Torner Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia. SEFH Congress (Virtual) October 2021 2021

4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
------	-------	---



Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Eau pour préparation injectable	 A l'abri de la lumière
 Jour	 NaCl 0,9% ou glucose 5%
 Non précisée	 Lumière
 Heure	 Polyvinyl chlorure
 Glucose 5%	 Polyéthylène
 Ethylène vinyl acétate	 Chlorure de sodium 0,9%
 Seringue polypropylène	 Elastomère en polyisoprène
 Non précisé	 Stabilité en mélange
 Solvant	 Molécule
RL Ringer lactate	 Chlorure de sodium 0,45%
\emptyset Aucun	 Facteur influençant la stabilité
 Provoque	 Dégradation
 Compatibilités	 Compatible
 Nutrition parentérale (mélange ternaire)	 Précipitation immédiate
 Incompatible	 Incompatibilité non précisée
 Turbidité en 1 heure	 Nutrition parentérale (mélange binaire)
 Modification du pH > 1 unité pH	 NaHCO ₃
 Instabilité chimique	 Dégagement gazeux
 Solvant spécifique	 Précipitation en 1 heure
 Turbidité immédiate	 Précipitation en 2 heures
 Voie d'administration	 Perfusion intraveineuse
 Perfusion continue	 Intramusculaire
 Bibliographie	 Dictionnaire